Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BGB-10188 by BeiGene for Epithelial Ovarian Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
BGB-10188 by BeiGene for Peritoneal Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Fallopian Tube Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
BGB-10188 by BeiGene for Esophageal Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Metastatic Melanoma: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
BGB-10188 by BeiGene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
BGB-10188 by BeiGene for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
BGB-10188 by BeiGene for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
BGB-10188 by BeiGene for Cervical Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Endometrial Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
BGB-10188 by BeiGene for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
BGB-10188 by BeiGene for Nasopharyngeal Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Hepatocellular Carcinoma: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Gastric Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Ovarian Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Epithelial Ovarian Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
BGB-10188 by BeiGene for Peritoneal Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
BGB-10188 by BeiGene for Fallopian Tube Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...